Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Conduit Pharmaceuticals Inc. (CDTTW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: CDTTW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -64.29% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2 | 52 Weeks Range 0.01 - 0.05 | Updated Date 05/21/2025 |
52 Weeks Range 0.01 - 0.05 | Updated Date 05/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -168.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 552357 |
Shares Outstanding - | Shares Floating 552357 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Conduit Pharmaceuticals Inc.
Company Overview
History and Background
Conduit Pharmaceuticals Inc., was founded to accelerate the development and commercialization of innovative therapies. They focus on acquiring and developing clinical-stage drug candidates that address unmet medical needs.
Core Business Areas
- Drug Development: Focused on identifying, acquiring, and developing innovative therapies in clinical stages.
- Commercialization: Preparing and launching therapies upon successful clinical development and regulatory approval.
Leadership and Structure
Conduit's leadership team comprises experienced pharmaceutical executives and scientists. The organizational structure is designed to support efficient drug development and commercialization processes.
Top Products and Market Share
Key Offerings
- AZD1656 (Ecalta): A potential treatment for various diseases. Market share is nascent but it is focusing on unmet needs in the market. Competitors depend on the specific indications pursued by Conduit.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The market is driven by the increasing prevalence of chronic diseases and advancements in biotechnology.
Positioning
Conduit is positioned as a company specializing in the efficient advancement of clinical stage products. Its competitive advantage lies in its acquisition strategy and streamlined development approach.
Total Addressable Market (TAM)
The total addressable market depends on the indication of the drugs under development. Conduit aims to capture a portion of this TAM by addressing unmet needs with its therapies.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Targeted acquisition strategy
- Pipeline of clinical-stage drug candidates
- Focus on unmet medical needs
Weaknesses
- Reliance on successful clinical trials
- Dependency on regulatory approvals
- Limited commercial infrastructure
- Potential for competition from larger pharmaceutical companies
Opportunities
- Expansion of pipeline through acquisitions
- Partnerships with larger pharmaceutical companies
- Successful commercialization of lead candidates
- Exploitation of unmet needs in specific therapeutic areas
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established players
- Patent expirations
Competitors and Market Share
Key Competitors
- ALNY
- CRSP
- VRTX
Competitive Landscape
Conduit Pharmaceuticals Inc. faces significant competition from established pharmaceutical companies. Its success will depend on differentiating its therapies and executing its development strategy.
Major Acquisitions
Arex Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 200
- Strategic Rationale: Conduit acquired Arex to add more clinical drugs to its pipeline and revenue.
Growth Trajectory and Initiatives
Historical Growth: Conduit Pharmaceuticals Inc.'s historical growth is characterized by acquisitions and clinical developments. The focus has been on building a pipeline of clinical-stage drug candidates.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals. Analyst estimates depend on their drugs entering the markets.
Recent Initiatives: Recent initiatives include the acquisition of novel drug candidates and the advancement of clinical trials.
Summary
Conduit Pharmaceuticals is a pharmaceutical firm focusing on developing new medicines. It has a small market cap and only has one major drug in development. The market is already highly competitive with established firms. To be successful it will need to continue acquiring viable therapies and excel in clinical trials. The company does have sufficient cash to meet obligations for at least the next year.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry news
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Conduit Pharmaceuticals Inc.
Exchange NASDAQ | Headquaters Naples, FL, United States | ||
IPO Launch date 2023-09-25 | Founder, CEO & Director Dr. Andrew Regan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.conduitpharma.com |
Full time employees 6 | Website https://www.conduitpharma.com | ||
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.